LTRN Stock Summary and Trading Ideas (Lantern Pharma | NASDAQ:LTRN)

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Lantern Pharma trades on the NASDAQ stock market under the symbol LTRN.

As of March 20, 2026, LTRN stock price declined to $2.13 with 32,914 million shares trading.

LTRN has a beta of 0.89, meaning it tends to be less sensitive to market movements. LTRN has a correlation of 0.06 to the broad based SPY ETF.

LTRN has a market cap of $23.82 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, LTRN traded as high as $11.99 and as low as $2.03.

The top ETF exchange traded funds that LTRN belongs to (by Net Assets): VTI, VXF, MEDX, IWC, DFSU.

LTRN has underperformed the market in the last year with a price return of -43.2% while the SPY ETF gained +15.6%. LTRN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.7% and -22.0%, respectively, while the SPY returned -4.7% and -4.8%, respectively.

LTRN support price is $2.03 and resistance is $2.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LTRN shares will trade within this expected range on the day.